The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global veterinary pain management market reached a value of US$ XX Billion in 2021. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Veterinary pain management refers to various drugs and drug combinations administered to animals for providing relied from chronic pain. It involves the observation of behavioral cues and anticipating the type, severity and duration of the pain. The treatment involves physical compresses, massages, therapy, rehabilitation, acupuncture, laser therapy and the administration of therapeutic and antianxiety drugs. These drugs can be administered orally, parenterally or topically. Veterinary pain management involves implementing changes in housing conditions, diet and level of interaction with other animals and humans. It is effective against acute surgical, traumatic and disease-related pain and also aids in improving the overall health of the animal.
The increasing domestication of animals, along with the rising awareness regarding pet health among the masses, is one of the key factors driving the growth of the market. Moreover, the convenient availability of pain management products and devices, including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), laser devices and local anesthetics, is providing a thrust to the market growth. These solutions provide relief from the pain caused by musculoskeletal disorders, radiotherapy-induced pain, chemotherapy, osteoarthritis and mastitis. In line with this, the widespread adoption of laser therapy as an effective solution for pain management is also contributing to the market growth. Laser therapy provides significant pain-relief and also aids in regenerating nerve tissue post-surgery. Additionally, a significant increase in the livestock population suffering from cancer, abdominal and neuropathic pain is also creating a positive outlook for the market. Other factors, including the rising prevalence of inflammation and pain-causing diseases in domesticated animals, along with the widespread adoption of pet insurance services, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global veterinary pain management market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, animal type, application and end user.
Breakup by Product:
Breakup by Animal Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Assisi Animal Health, Bayer AG, Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Ceva Sante Animale, Chanelle Pharma, Dechra Pharmaceuticals PLC, Eli Lilly and Company, Idexx Laboratories Inc., Merck & Co. Inc., Norbrook, Vetoquinol S.A. and Zoetis Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Animal Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Assisi Animal Health, Bayer AG, Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Ceva Sante Animale, Chanelle Pharma, Dechra Pharmaceuticals PLC, Eli Lilly and Company, Idexx Laboratories Inc., Merck & Co. Inc., Norbrook, Vetoquinol S.A. and Zoetis Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at